纳斯达克 · USD

enGene Therapeutics Inc. (ENGNW) 股票分析

enGene Therapeutics Inc.（ENGNW）是在纳斯达克上市的股票，以美元交易。

ENGNW

$0.23

+$0.01 (+4.55%)

2026年9月4日 · 收盘

这是一只衍生品——enGene Therapeutics Inc.（ENGN）普通股的认股权证。

发行人的基本面数据显示在发行人页面，而非本页。

查看ENGN →

价格走势

悬停查看每日收盘价。虚线表示区间起始价。

ENGNW 关键统计数据

数据截至2026年9月4日

交易

开盘价: $2.10
前收盘价: $0.22
当日波动区间: 0.22–0.23
52周波动区间: 0.22–0.23
成交量: 1.21K
Beta系数: −0.28

仅显示公司披露的指标。数据由Yahoo Finance通过yfinance提供。每日更新。

ENGNW 历年回报率

历年回报率根据每日收盘价计算。不完整年度以浅色显示并标有星号。

年份	回报率
2026 (不完整年度)	−92.33%
2025 (不完整年度)	+20.48%

数据截至2026年9月4日。

关于enGene Therapeutics Inc.

enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.

公司简介以英文显示。

访问官网 →

enGene Therapeutics Inc. (ENGNW) 股票分析

价格走势

ENGNW 关键统计数据

ENGNW 历年回报率

最新新闻

enGene to Participate in Upcoming Investor Conferences

enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market

enGene Therapeutics Inc. (ENGN) Discusses Market Insights and Clinical Development in Non-Muscle Invasive Bladder Cancer Transcript

enGene Therapeutics Inc. (ENGN) Discusses Market Insights and Clinical Development in Non-Muscle Invasive Bladder Cancer - Slideshow

关于enGene Therapeutics Inc.